



(43) International Publication Date  
14 April 2016 (14.04.2016)

(10) International Publication Number  
**WO 2016/057271 A1**

- (51) **International Patent Classification:**  
**A61F 13/00** (2006.01) **A61F 13/02** (2006.01)
- (21) **International Application Number:**  
PCT/US20 15/0530 18
- (22) **International Filing Date:**  
29 September 2015 (29.09.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
62/060,098 6 October 2014 (06.10.2014) US  
62/096,669 24 December 2014 (24.12.2014) US
- (71) **Applicant:** **KCI LICENSING, INC.** [US/US]; Legal Department-Intellectual Property, P.O. Box 659508, San Antonio, TX 78265-9508 (US).
- (72) **Inventors:** **LOCKE, Christopher, Brian**; 6 Bosworth Mews, Bournemouth, Dorset BH9 3SD (GB). **ANDREWS, Brian**; 36 Charborough Way, Sturminster Marshall, Wimborne, Dorset BH21 4DH (GB). **ROBINSON, Timothy, Mark**; 27 Wellington Terrace, Basingstoke, Hampshire RG23 8HH (GB).
- (74) **Agents:** **WELCH, Gerald, T.** et al; Harness Dickey & Pierce, P.L.C., 5445 Corporate Drive, Suite 200, Troy, MI 48098 (US).


(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report (Art. 21(3))

(54) **Title:** ION EXCHANGE ABSORBENT SYSTEMS, APPARATUSES



**FIG. 1**

(57) **Abstract:** Systems and apparatuses for increasing liquid absorption are described. Some embodiments may include a dressing having an absorbent layer containing super-absorbent material as well as ionic-exchange media (IEM). In some embodiments, the absorbent layer may include absorbent fibers. The absorbent fibers may each include a super-absorbent core surrounded by a water-permeable layer onto which ionic-exchange media (IEM) may be grafted. As liquid comes into contact with the IEM, its ionic nature may be reduced, therefore protecting the absorbent qualities of the super-absorbent material.



WO 2016/057271 A1

**ION EXCHANGE ABSORBENT SYSTEMS, APPARATUSES, AND METHODS**

[0001] This application claims priority to and the benefit of U.S. Provisional Patent Application No. 62/060,098, filed October 6, 2014, entitled "Multi-Function Dressing Structure for Negative Pressure Therapy," to Robinson et al., and U.S. Provisional Patent Application No. 62/096,669, filed December 24, 2014, entitled "Ion Exchange Absorbent Systems, Apparatuses, and Methods, to Locke et al., both of which are hereby incorporated by reference.

**TECHNICAL FIELD**

[0002] The invention set forth in the appended claims relates generally to treating tissue sites and processing fluids. More particularly, but not by way of limitation, the subject matter described herein relates to absorbents with ion-exchange media.

**BACKGROUND**

[0003] While the benefits of using absorbent materials in wound care are known, the cost and complexity of treating particular types of wounds can be a limiting factor, particularly when combined with negative-pressure therapy. In particular, wound dressings that incorporate absorbents formed of superabsorbent polymers often provide a practical absorption capacity that is less than the rated absorption capacity. This may necessitate the use of additional absorbent or increase the number of dressing changes needed to treat a tissue site. Increasing the amount of absorbent used and the number of dressing changes can negatively affect the efficacy and cost of wound care.

## BRIEF SUMMARY

[0004] According to an illustrative embodiment, a fiber may include an absorbent core, a filter layer, and an ion-exchange media. The filter layer may be disposed around the absorbent core. The ion-exchange media may be disposed in the filter layer and adapted to reduce an ionic concentration of a fluid.

[0005] According to another illustrative embodiment, an absorbent dressing for treating a tissue site may include an ion-exchange media and an absorbent. The ion-exchange media may be adapted to reduce an ionic concentration of the fluid. The absorbent material may be adapted to absorb fluid from the tissue site.

[0006] According to yet another illustrative embodiment, a system for treating a tissue site may include a reduced-pressure source, an absorbent layer, and a drape. The reduced-pressure source may be for providing reduced pressure. The absorbent layer may be adapted to be in fluid communication with the reduced-pressure source. The absorbent layer may include an absorbent material adapted to absorb fluid from the tissue site, and an ion-exchange media adapted to reduce an ionic concentration of the fluid. The drape may be adapted to cover the absorbent layer.

[0007] According to still another illustrative embodiment, a container for storing fluids from a tissue site may include a body and an absorbent layer. The body may include an interior portion, a fluid inlet, and a fluid outlet. The absorbent layer may include an absorbent material and an ion-exchange media adapted to reduce an ionic concentration of fluid in the interior portion.

[0008] According to still another illustrative embodiment, a method for treating a tissue site may include disposing an absorbent layer proximate to the tissue site and attaching the absorbent layer to the tissue site with a drape. The absorbent layer may include an absorbent material and an ion-exchange media adapted to reduce an ionic concentration of a fluid drawn into the absorbent layer. The method may also include disposing a manifold between the tissue site and the absorbent layer, fluidly coupling a reduced-pressure source to the manifold, and supplying reduced pressure to the tissue site to draw fluid from the tissue site to the absorbent layer.

[0009] According to still another illustrative embodiment, a system for treating a tissue site may include a reduced-pressure source, a fluid storage member, a manifold, a drape, and an absorbent layer. The fluid storage member may be adapted to be in fluid

communication with the tissue site and the reduced-pressure source. The manifold may be adapted to receive reduced pressure and distribute the reduced pressure to the tissue site. The drape may be adapted to cover the manifold and provide a substantially fluid-tight seal at the tissue site. The absorbent layer may include a carrier material and a plurality of multi-layer fibers. Each multi-layer fiber may include an ion-exchange media disposed around an absorbent core.

[0010] Other aspects, features, and advantages of the illustrative embodiments will become apparent with reference to the drawings and detailed description that follow.

**BRIEF DESCRIPTION OF THE DRAWINGS**

[0011] FIGURE 1 is a schematic diagram of an illustrative embodiment of an absorbent layer;

[0012] FIGURE 2 is a sectional schematic diagram of an absorbent fiber of the absorbent layer of FIGURE 1;

[0013] FIGURE 3 is a schematic diagram of another illustrative embodiment of an absorbent layer;

[0014] FIGURE 4 is a schematic diagram of another illustrative embodiment of an absorbent layer;

[0015] FIGURE 5 is a functional block diagram illustrating a reduced-pressure therapy system that may be associated with some embodiments of an absorbent layer; and

[0016] FIGURE 6 is a sectional view of an illustrative embodiment of a container of the reduced-pressure therapy system of FIGURE 5.

## DESCRIPTION OF EXAMPLE EMBODIMENTS

[0017] In the following detailed description of non-limiting, illustrative embodiments, reference is made to the accompanying drawings that form a part hereof. Other embodiments may be utilized, and logical, structural, mechanical, electrical, and chemical changes may be made without departing from the scope of the appended claims. To avoid detail not necessary to enable those skilled in the art to practice the embodiments described herein, the description may omit certain information known to those skilled in the art. The following detailed description is non-limiting, and the scope of the illustrative embodiments are defined by the appended claims.

[0018] FIGURE 1 is a schematic diagram of an exemplary embodiment of an absorbent layer 102. The absorbent layer 102 may include or consist of a woven or non-woven matrix, such as a fiber matrix 104. The fiber matrix 104 may be formed from long fibers, such as fibers 106, which may be bundled or twisted together. The fiber matrix 104 may include the fibers 106 arranged along both the length and width of the absorbent layer 102. The absorbent layer 102 may include more than one layer of the fiber matrix 104. For example, in some embodiments, the number of layers of fiber matrices 104 can be tailored to a particular type of wound or tissue site and the amount of fluid or exudates expected to be released from the wound.

[0019] FIGURE 2 is a sectional schematic diagram of an example embodiment of the fiber 106, illustrating additional details that may be associated with some embodiments. The fiber 106 may include multiple layers. For example, in the embodiment of FIGURE 2, the fiber 106 may include an absorbent core, such as a core 208, and a filter layer 210.

[0020] The core 208 may include or consist of an absorbent material, which may be a material used to hold, stabilize, and/or solidify liquids. The absorbent material may be a hydrophilic material. The absorbent material may provide an absorption gradient to draw or otherwise wick fluid away from the tissue site. Fluid from the tissue site may be drawn by the absorption gradient and then absorbed by the absorbent material. The absorbent material may retain or bond to the fluid in conjunction with a physical or chemical change to the absorbent material. The absorbent material may, for example, gel, increase in viscosity, or otherwise thicken upon contact with fluid from the tissue site, thereby trapping the fluid. The wicking properties of the absorbent material may help to quickly draw fluid, *e.g.* exudate,

away from the tissue site, and thus may prevent the accumulation of fluid at or near the tissue site.

[0021] In some embodiments, the absorbent material may comprise a super-absorbent material. For example, the absorbent material may comprise one or more super-absorbent materials, such as, carboxymethyl cellulose (CMC), or a carboxymethylcellulose salt, a cross-linked hydrophilic acrylic, or a cross-linked hydrophilic acrylic salt, or an acrylamide. In some embodiments, for example, the super-absorbent material may be a super-absorbent polymer (SAP), such as the type commonly referred to as a hydrogel or a hydrocolloid. Generally, relative to their mass, a SAP can absorb and retain large quantities of liquid, and in particular, water. Medical disposables, such as canisters and dressings, can use a SAP to retain and stabilize or solidify wound fluids and other exudate.

[0022] A SAP may be formed in several ways, for example, by gel polymerization, solution polymerization, or suspension polymerization. Gel polymerization may involve blending of acrylic acid, water, cross-linking agents, and ultraviolet (UV) initiator chemicals. The blended mixture may be placed into a reactor where the mixture is exposed to UV light to cause crosslinking reactions that form the SAP. The mixture may be dried and shredded before subsequent packaging and/or distribution. Solution polymerization may involve a water-based monomer solution that produces a mass of reactant polymerized gel. The monomer solution may undergo an exothermic reaction that drives the cross-linking of the monomers. Following the cross-linking process, the reactant polymer gel may be chopped, dried, and ground to its final granule size. Suspension polymerization may involve a water-based reactant suspended in a hydrocarbon-based solvent.

[0023] In general, SAPs can absorb liquids by bonding with water molecules through hydrogen bonding. Hydrogen bonding involves the interaction of a polar hydrogen atom with an electronegative atom. As a result, SAPs can absorb water based on the ability of the hydrogen atoms in each water molecule to bond with the hydrophilic polymers of the SAP having electronegative ionic components. High-absorbing SAPs can be formed from ionic cross-linked hydrophilic polymers such as acrylics and acrylamides in the form of salts or free acids.

[0024] Because SAPs are ionic, they can be affected by the soluble ionic components within a solution being absorbed and may, for example, absorb less saline than pure water. The lower absorption rate of saline is caused by the sodium and chloride ions blocking some of the water absorbing sites on a SAP. If fluid absorbed by a SAP is a solution containing

dissolved mineral ions, fewer hydrogen atoms of the water molecules in the solution may be free to bond with the SAP. Thus, the ability of a SAP to absorb and retain fluid may be dependent upon the ionic concentration of the fluid. For example, a SAP may absorb and retain de-ionized water up to 500 times the weight of the dry SAP. In volumetric terms, a SAP may absorb fluid volumes as high as 30 to 60 times the dry volume of the SAP. Other fluids having a higher ionic concentration may be absorbed at lower quantities. For example, a SAP may only absorb and retain a solution that is 0.9% salt (NaCl) up to 50 times the weight of the dry SAP.

[0025] Since wound fluids may contain salts, such as sodium, potassium, and calcium, the absorption capacity of a SAP may be significantly reduced when used in wound treatment applications. The reduction in absorption capacity may necessitate using additional quantities of a SAP that can significantly add to the overall bulkiness of the dressing or fluid storage device. Additionally, in many therapy systems, using additional quantities of a SAP may not be possible due to size limitations of the dressing or container.

[0026] The systems, apparatuses, and methods described herein can overcome these shortcomings and others by providing absorbent fibers with ionic-exchange media (IEM). Thus, a simplified design for removing ionic material from wound fluid media combined with super-absorbing functionality is provided. Such a design can be incorporated as part of a wound dressing, a fluid-handling canister, or a storage container.

[0027] Referring still to FIGURE 2, for example, the core 208 may be at least partially enclosed within the filter layer 210, and an IEM 212 may be disposed within the filter layer 210. In some embodiments, the filter layer 210 may be coated onto the outside of the core 208, and may be a water-soluble or water-swelling polymer. Water-soluble or water-swelling polymers may include cross-linked polyvinyl alcohol, polyvinyl pyrrolidone, polyurethane, polyacrylamide, and polyethylene oxide. The IEM 212 may be ion-exchange resins in the form of beads or other particles, which may be grafted onto the surface of the filter layer 210. Alternatively, the ion-exchange resins may be grafted onto polystyrene and dispersed throughout the filter layer 210. The diameter of the fiber 106 may be in the range of about 1-50 microns, and more typically in the range of about 5-25 microns, depending on the dimensions of the core 208 and filter layer 210 that may be desired or appropriate for a particular application.

[0028] The IEM 212 may reduce the number of ionized particles within the wound fluid coming into contact with the core 208. For example, the IEM 212 may provide a



reduction of the number of ionized particles within the wound fluid somewhere in the range of 1% - 80%. In some preferred embodiments, the IEM 212 may provide an approximately 25% reduction in ionized particle concentration within the wound fluid. The IEM 212 may be adapted to provide an exchange of ions between two electrolytes, or between an electrolyte solution and a complex. An electrolyte is a compound that ionizes when dissolved in a suitable ionizing solvent, such as water. An electrolyte solution may contain a dissolved salt, such as NaCl. A complex may be an atom or ion having a surrounding array of bound molecules or anions known as ligands or complexing agents. IEM can replace cations and anions in an electrolyte or an electrolyte solution as the electrolyte or electrolyte solution interacts with the IEM. Cations are ions having a net positive charge, for example, Na<sup>+</sup>. Cations may be replaced in the electrolyte or electrolyte solution with hydrogen (H<sup>+</sup>) ions of the IEM. Anions are ions having a net negative charge, for example, Cl<sup>-</sup>. Anions may be replaced in the electrolyte or electrolyte solution with hydroxyl (OH<sup>-</sup>) ions of the IEM. The H<sup>+</sup> and OH<sup>-</sup> ions may combine in the electrolyte or electrolyte solution to form water.

[0029] In some embodiments, the IEM 212 may be porous beads formed from cross-linked polymers, such as polystyrene, that are doped or grafted with acidic polymers. An example of an acidic polymer may include poly(2-acrylamido-2-methyl-1-propanesulfonic acid) or polyAMPS. The polyAMPS can exchange positively charged salt ions for H<sup>+</sup>. An example of an alkaline polymer may include poly(acrylamido-N-propyltrimethylammonium chloride) or polyAPTAC. The polyAPTAC exchange negatively charged salt ions for OH<sup>-</sup>.

[0030] The IEM 212 of the filter layer 210 may also include a mixture of both cation-exchange media 214 and anion-exchange media 216 to form a mixed bed ion-exchange media that can simultaneously absorb both anions and cations. Non-limiting examples of the mixed bed media include AMBERLITE IRN150 and TMD-8. The IEM may be formed of ion-exchange resins, zeolites, montmorillonite, bentonites, clay, or soil humus, for example. Ion-exchange resins, also known as ion-exchange polymers, are insoluble matrices normally in the form of small beads fabricated from an organic polymer substrate. Ion-exchange resins may have pores on the surface that trap and release ions. Ion-exchange resins can include cross-linked polystyrene, for example. Zeolites are microporous, aluminosilicate minerals. Zeolites have a porous structure that allow cations, such as Na<sup>+</sup>, K<sup>+</sup>, Ca<sup>2+</sup>, and Mg<sup>2+</sup>, for example, to be accommodated by the zeolite. Common zeolites include analcime, chabazite, clinoptilolite, heulandite, natrolite, phillipsite, and stilbite, for example. In addition to the above materials, other ion-exchange media include activated charcoal, both particulate and in

the form of fabrics or non-wovens, for example, and Zorflex, also known as Chemviron Carbon. Chemviron Carbon may also be known as 100% activated carbon.

[0031] The core 208 may be in the form of a super-absorbent fiber, such as one made from an alginate or particles fused together, for example, carboxymethyl cellulose (CMC) or polyacrylic acid. In some embodiments, super-absorbent fibers may be formed or manufactured by various spinning processes, such as, but not limited to, wet spinning, dry spinning, melt spinning, gel spinning, or electro-spinning. As a first step in the process, the fiber-forming polymer may be converted into a fluid state. The polymer can be melted, dissolved in a solvent, or chemically treated to form a soluble derivative. The molten polymer may be extruded through a spinneret, a multi-pored device, to form fibers.

[0032] In some embodiments, the fibers 106 may be formed by simultaneously extruding the super-absorbent core material and the filter layer material containing the ion-exchange media using a co-extrusion process. For example, in some embodiments, the co-extrusion process involves the use of an extruder to create the outer filter layer material, which may contain the ion-exchange media, and an auxiliary system for injecting or filling the outer filter layer material with the super-absorbent core material.

[0033] Referring more specifically to FIGURE 3, a schematic diagram illustrating another exemplary embodiment of a fiber matrix is shown. A fiber matrix 302 as illustrated in FIGURE 3 may include short fibers 306 having characteristics similar or analogous to the fibers 106. For example, the fibers 306 may include a core, such as the core 208 encapsulated by an IEM layer, such as the filter layer 210. In some example embodiments, the fibers 306 may be dispersed in a carrier material, such as a carrier 318. The fibers 306 may have a variety of sizes or shapes, depending on a variety of factors, including the amount of liquids anticipated to be released by a tissue site, but preferably have a diameter in the range of about 1-50 microns, and more typically in the range of about 5-25 microns. In some embodiments, the carrier 318 may be a continuous polymer water-permeable matrix, perforated to permit transmission of negative pressure. Such polymers may include polymers and copolymers of polyvinyl alcohol, polyacrylic acid and its salts (sodium and potassium), carboxymethyl cellulose (CMC), other cellulose, polyacrylamides, polyurethanes, and polyethylene oxides and glycols. In some embodiments, the carrier may also be a textile, formed from woven or non-woven fibers, for example, poly- and copoly-ester, polyolefin, cellulose, or blends of any of these materials.

[0034] FIGURE 4 illustrates another exemplary embodiment of a fiber matrix. The fiber matrix 402 of FIGURE 4 may include fibers 420, which may include multiple layers. For example, in the embodiment of FIGURE 4, the fibers 420 may include an absorbent strand, such as a core 422 and filter strands 423 having IEM. In some embodiments, the core 422 may be in the form of a super-absorbent strand, and the filter strands may be twisted around the core 422. In some embodiments, fibers such as the fibers 420 may be dispersed in a carrier material, such as a carrier 418. The filter strands 423 may include acidic-exchange strands 424, which may include acidic-exchange media 428, and alkaline-exchange strands 426, which may include alkaline-exchange media 430. In some embodiments, the filter strands 423 may include cation-exchange resins or anion-exchange resins. In other embodiments, the filter strands 423 may include a combination of cation- and anion-exchange resins.

[0035] In the example embodiment of FIGURE 4, the filter strands 423 can reduce or remove the ionic material from fluid before the fluid contacts the core 422. By including each of the three functional elements, namely a super-absorbent core, the acidic ion-exchange medium, and the alkaline ion-exchange medium, as separate strands, manufacturing of the fiber 420 can be simplified. For example, a fiber production or spinning method where four or more feed-stock streams are required to remain consistent with each other to produce a single multi-component fiber may not be needed.

[0036] Absorbent fibers with ion-exchange media, such as the fiber 106 or the fiber 420, may have many beneficial or advantageous applications. For example, an absorbent layer having absorbent fibers with ion-exchange media, such as the fiber matrix 104, the fiber matrix 302, or the fiber matrix 402, may be particularly advantageous for treating wounds with reduced pressure. Treatment of wounds or other tissue with reduced pressure may be commonly referred to as "reduced-pressure therapy," but is also known by other names, including "negative-pressure wound therapy," "negative-pressure therapy," "vacuum therapy," and "vacuum-assisted closure," for example. Reduced-pressure therapy may provide a number of benefits, including migration of epithelial and subcutaneous tissues, improved blood flow, and micro-deformation of tissue at a wound site. Together, these benefits can increase development of granulation tissue and reduce healing times.

[0037] FIGURE 5 is a schematic diagram of an example embodiment of a reduced-pressure therapy system 500 that may include absorbent fibers with an ion-exchange media. For example, the reduced-pressure therapy system 500 may include a dressing 532, which

can be positioned proximate to a tissue site, and a reduced-pressure source 534 for providing reduced pressure to the dressing 532. In some embodiments, the dressing 532 may include a manifold 540, an absorbent layer 502, and a drape 538. The absorbent layer 502 may incorporate any combination, in whole or in part, of suitable features, structures, or elements of the fiber matrices or fibers with ion-exchange media described herein. For example, the absorbent layer 502 may incorporate the fiber matrix 104, the fiber matrix 302, the fiber matrix 402, or any suitable combination of features of these embodiments. The dressing 532 may be fluidly coupled to the reduced-pressure source 534. The reduced-pressure therapy system 500 may also include an exudate container, such as container 542, coupled to the dressing 532 and to the reduced-pressure source 534.

[0038] The term "tissue site" may refer to a wound or defect located on or within tissue, including without limitation, bone tissue, adipose tissue, muscle tissue, neural tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, or ligaments. A tissue site may include chronic, acute, traumatic, subacute, and dehiscent wounds, partial-thickness burns, ulcers (such as diabetic, pressure, or venous insufficiency ulcers), flaps, and grafts, for example. The term "tissue site" may also refer to areas of any tissue that are not necessarily wounded or defective, but are instead areas in which it may be desirable to add or promote the growth of additional tissue. For example, reduced pressure may be used in certain tissue areas to grow additional tissue that may be harvested and transplanted to another tissue location.

[0039] A reduced-pressure source, such as the reduced-pressure source 534, may be a reservoir of air at a reduced pressure, or may be a manually or electrically-powered device that can reduce the pressure in a sealed volume, such as a vacuum pump, a suction pump, a wall suction port available at many healthcare facilities, or a micro-pump, for example. The reduced-pressure source may be housed within or used in conjunction with other components, such as sensors, processing units, alarm indicators, memory, databases, software, display devices, or user interfaces that further facilitate reduced-pressure therapy. While the amount and nature of reduced pressure applied to a tissue site may vary according to therapeutic requirements, the pressure may be a rough vacuum between about -5 mm Hg (-667 Pa) and about -500 mm Hg (-66.7 kPa). In some embodiments, the pressure may be between about -75 mm Hg (-9.9 kPa) and about -300 mm Hg (-39.9 kPa).

[0040] In general, exudates and other fluids may flow toward lower pressure along a fluid path. Further, fluids may be attracted to flow through permeable materials along a path

of increasing hydrophilicity or absorbency among the materials. Thus, the term "downstream" may refer to components that are further along a fluid path than components that may be referred to as "upstream." Similarly, it may be convenient to describe certain features in terms of fluid "inlet" or "outlet" in such a frame of reference. This orientation is generally presumed for purposes of describing various features and components of negative-pressure therapy systems herein. However, the fluid path may also be reversed in some applications (such as by substituting a positive-pressure source for a negative-pressure source) and this descriptive convention should not be construed as a limiting convention.

[0041] "Reduced pressure" may refer to a pressure less than a local ambient pressure, such as the ambient pressure in a local environment external to a sealed therapeutic environment. The local ambient pressure may also be the atmospheric pressure at which a patient is located. Further, the pressure may be less than a hydrostatic pressure associated with tissue at the tissue site. Unless otherwise indicated, values of pressure stated herein are gauge pressures. Similarly, references to increases in reduced pressure typically refer to a decrease in absolute pressure, while decreases in reduced pressure typically refer to an increase in absolute pressure.

[0042] The components of the reduced-pressure therapy system 500 may be coupled directly or indirectly. Components may be fluidly coupled to each other to provide a path for transferring fluids (for example, liquid and/or gas) between the components. In some exemplary embodiments, components may be fluidly coupled with conduits, such as tubes. A "tube," as used herein, may refer to a pipe, hose, conduit, or other elongated structure with one or more lumina adapted to convey fluids between two ends. In some exemplary embodiments, components may additionally or alternatively be coupled by virtue of physical proximity, being integral to a single structure, or being formed from the same piece of material. Coupling may also include mechanical, thermal, electrical, or chemical coupling (such as a chemical bond) in some contexts.

[0043] The manifold 540 may be adapted to be in fluid communication with a tissue site, the absorbent layer 502, and the drape 538. For example, the manifold 540 may be placed within, over, on, or otherwise proximate to a tissue site. The absorbent layer 502 may be placed between the tissue site or the manifold 540 and the drape 538. The drape 538 may be placed over the manifold 540 and the absorbent layer 502 and sealed to tissue proximate to the tissue site. The tissue proximate to the tissue site may be undamaged epidermis peripheral to the tissue site. Thus, the dressing 532 can provide a sealed therapeutic

environment proximate to the tissue site, substantially isolating the tissue site from the external environment. The reduced-pressure source 534 can reduce pressure in the sealed therapeutic environment. Reduced pressure applied uniformly through the manifold 540 in the sealed therapeutic environment can induce macrostrain and microstrain in the tissue site, as well as remove exudates and other fluids from the tissue site.

[0044] In some embodiments, the manifold 540 may be adapted to contact a tissue site. The manifold 540 may be partially or fully in contact with a tissue site. If a tissue site extends into tissue from a tissue surface, for example, the manifold 540 may partially or completely fill the tissue site. In other exemplary embodiments, the manifold 540 may be placed over a tissue site. The manifold 540 may take many forms, and may have many sizes, shapes, or thicknesses depending on a variety of factors, such as the type of treatment being implemented or the nature and size of the tissue site. For example, the size and shape of the manifold 540 may be adapted to the contours of deep and irregular shaped tissue sites.

[0045] The manifold 540 may comprise a substance or structure adapted to distribute reduced pressure across a tissue site, remove fluids from across a tissue site, or both. In some exemplary embodiments, the manifold 540 may also facilitate delivering fluids across a tissue site, for example, if a fluid path is reversed or a secondary fluid path is provided. The manifold 540 may include flow channels or pathways that distribute fluids provided to and removed from a tissue site around the manifold 540. In one exemplary embodiment, the flow channels or pathways may be interconnected to improve distribution of fluids provided to or removed from a tissue site. For example, cellular foam, open-cell foam, porous tissue collections, and other porous material, such as gauze or felted mat may include structural elements arranged to form flow channels. Liquids, gels, and other foams may also include or be cured to include flow channels configured to distribute fluid across a tissue site.

[0046] In one exemplary embodiment, the manifold 540 may be a porous foam material having interconnected cells or pores adapted to distribute reduced pressure across a tissue site in a substantially uniform manner. The foam material may be either hydrophobic or hydrophilic. In one non-limiting example, the manifold 540 can be an open-cell, reticulated polyurethane foam such as GranuFoam® dressing available from Kinetic Concepts, Inc. of San Antonio, Texas.

[0047] In an example embodiment in which the manifold 540 may be made from a hydrophilic material, the manifold 540 may also wick fluid away from the tissue site, while continuing to distribute reduced pressure to the tissue site. The wicking properties of the

manifold 540 may draw fluid away from the tissue site by capillary flow or other wicking mechanisms. An example of a hydrophilic foam is a polyvinyl alcohol, open-cell foam such as V.A.C. WhiteFoam® dressing available from Kinetic Concepts, Inc. of San Antonio, Texas. Other hydrophilic foams may include those made from polyether. Other foams that may exhibit hydrophilic characteristics include hydrophobic foams that have been treated or coated to provide hydrophilicity.

[0048] The manifold 540 may further promote granulation at the tissue site when pressure within the sealed therapeutic environment is reduced. For example, any or all of the surfaces of the manifold 540 may have an uneven, coarse, or jagged profile that can induce microstrains and stresses at the tissue site when reduced pressure is applied through the manifold 540 to a tissue site.

[0049] In one exemplary embodiment, the manifold 540 may be constructed from bioresorbable materials. Suitable bioresorbable materials may include, without limitation, a polymeric blend of polylactic acid (PLA) and polyglycolic acid (PGA). The polymeric blend may also include, without limitation, polycarbonates, polyfumarates, and caprolactones. The manifold 540 may further serve as a scaffold for new cell-growth, or a scaffold material may be used in conjunction with the manifold 540 to promote cell-growth. A scaffold is generally a substance or structure used to enhance or promote the growth of cells or formation of tissue, such as a three-dimensional porous structure that provides a template for cell growth. Illustrative examples of scaffold materials include calcium phosphate, collagen, PLA/PGA, coral hydroxy apatites, carbonates, or processed allograft materials.

[0050] The drape 538 is an example of a sealing member. A sealing member may be constructed to provide a fluid seal between two components or two environments, such as between a therapeutic environment and a local external environment. The sealing member may be, for example, an impermeable or semi-permeable, elastomeric film that can provide a seal adequate to maintain a reduced pressure at a tissue site for a given reduced-pressure source. For semi-permeable materials, the permeability generally should be low enough that a desired reduced pressure may be maintained. An attachment device may be used to attach a sealing member to an attachment surface, such as undamaged epidermis, a gasket, or another sealing member. The attachment device may take many forms. For example, an attachment device may be a medically-acceptable, pressure-sensitive adhesive that extends about a periphery, a portion of, or an entirety of the sealing member. Other exemplary embodiments

of an attachment device may include a double-sided tape, paste, hydrocolloid, hydrogel, silicone gel, organogel, or an acrylic adhesive.

[0051] In some embodiments, the reduced pressure developed by the reduced-pressure source 534 may be delivered through a tube to a connector. The connector may be a device configured to fluidly couple the reduced-pressure source 534 to the sealed therapeutic environment formed by the drape 538. In some embodiments, the connector may include a flange portion that couples to the drape 538 and a port portion that fluidly couples to the tube. In one exemplary embodiment, the connector may be a T.R.A.C.® Pad or Sensa T.R.A.C.® Pad available from Kinetic Concepts, Inc. of San Antonio, Texas. In other exemplary embodiments, the connector may also be a conduit inserted through the drape 538. The connector allows the reduced pressure to be delivered to the sealed therapeutic environment between the drape 538 and the tissue site. In some embodiments, the connector may extend through the drape 538 to the absorbent layer 502, but numerous arrangements are contemplated. The connector can deliver the reduced pressure through the drape 538 of the dressing 532 to the manifold 540.

[0052] The absorbent layer 502 is also preferably permeable to gases. For example, in some embodiments, the absorbent layer 502 may include fibers 106, in which the core 208 may comprise a SAP. Reduced pressure may be transferred with and through spaces or voids between the fibers 106 in such embodiments of the absorbent layer 502.

[0053] The container 542 is representative of a container, canister, pouch, or other storage component that can be used to manage exudates and other fluids withdrawn from a tissue site. In many environments, a rigid container may be preferred or required for collecting, storing, and disposing of fluids. In other environments, fluids may be properly disposed of without rigid container storage, and a re-usable container could reduce waste and costs associated with reduced-pressure therapy. Some exemplary embodiments of the reduced-pressure therapy system 500 may not include the container 542; instead, these exemplary embodiments of the therapy system 500 handle fluid storage with the dressing 532 and the absorbent layer 502.

[0054] FIGURE 6 is a sectional view illustrating additional details that may be associated with some embodiments of the container 542. In some embodiments, the container 542 comprises a body 644 having an interior 654. In some embodiments, an absorbent sheet 656 may be disposed within the interior 654 of the container 542. The



absorbent sheet 656 may include or may be formed from one or more fiber matrices, such as the fiber matrix 104, for example.

[0055] In some exemplary embodiments, the absorbent sheet 656 may substantially fill the interior 654. In other exemplary embodiments, the absorbent sheet 656 may fill only a portion of the interior 654. The interior 654 of the container 542 may be adapted to allow for the absorbent sheet 656 to expand if the absorbent sheet 656 absorbs fluid from a tissue site. In some embodiments, the container 542 may be rigid, and the absorbent sheet 656 may not substantially fill the interior 654, leaving space for expansion of the absorbent sheet 656. In some embodiments, the container 542 may be flexible, and the interior 654 may be configured to expand to accommodate expansion of the absorbent sheet 656. In addition, the amount and disposition of the absorbent sheet 656 within the interior 654 may vary as needed to allow fluid communication of reduced pressure through the container 542 to the dressing 532.

[0056] The container 542 may further include a fluid inlet 648 and a fluid outlet 652. In some embodiments, the fluid inlet 648 may pass through a wall of the container 542 to provide fluid communication between the interior 654 and an area outside of the container 542. In some embodiments, a tube 646 may fluidly couple to the fluid inlet 648 so that the tube 646 may provide fluid communication between the dressing 532 and the interior 654. The fluid outlet 652 may extend through a wall of the container 542 to provide fluid communication between the body interior 654 and an area outside of the container 112. In some embodiments, a tube 650 may be fluidly coupled to the fluid outlet 652 and may be further fluidly coupled to a reduced-pressure source, such as the reduced-pressure source 534, allowing for fluid communication between the reduced-pressure source and the interior 654. The fluid inlet 648 and the fluid outlet 652 may be positioned on the container 542 as shown in FIGURE 6. In other embodiments, the fluid inlet 648 and the fluid outlet 652 may be positioned in other locations to accommodate additional components of the reduced-pressure therapy system 500. For example, the container 542 may be combined with a reduced-pressure source. In this example, the fluid inlet 648 and the fluid outlet 652 may be disposed on other portions of the container 542 to accommodate the positioning of various components of the combined container 542 and a reduced-pressure source.

[0057] In operation, the reduced-pressure source 534 may supply reduced pressure to the dressing 532, including the manifold 540, and ultimately a tissue site. The reduced pressure may draw fluids out of the tissue site, and the manifold 540 may distribute the fluids

from the tissue site to the dressing 532. The fluids drawn from the tissue site may have a high ionic concentration. Upon reaching the dressing 532, the fluids may come into contact with the absorbent layer 502, which may include fibers with ion-exchange media, such as the fiber 106, the fiber 306, or the fiber 420. If wound fluid comes into contact with the fibers 106, for example, the ion-exchange media 212 in the filter layer 210 can exchange salt ions, such as sodium and chloride ions, with the fluid. The ionic salt content of the fluid may be removed or substantially reduced before contacting the core 208, thus enabling the core 208 to absorb a significantly higher amount of fluid.

[0058] In some embodiments, while much of the fluid drawn from a tissue site may be absorbed by the absorbent layer 502, some fluid may be drawn through the dressing 532. In other embodiments, the dressing 532 may not include the absorbent layer 502, or the absorbent layer 502 may not include ion-exchange media. Fluid not retained by the dressing 532 may be drawn to the container 542, and into the interior 654 of the container 542. Fluid drawn into the interior 654 may come into contact with the absorbent sheet 656 in the interior 654 of the container 542. The absorbent sheet 656 may include absorbent fibers with an ion-exchange fiber, as described above. An ion-exchange fiber can reduce the ionic concentration of fluid, as described above, before fluid is absorbed by the core of the absorbent fibers. Fluid passing into the core may have a reduced ionic concentration, allowing for increased absorption efficiency by the absorbent sheet 656, which can also increase the capacity of the container 542.

[0059] The systems, apparatuses, and methods described herein may provide significant advantages, some of which have already been mentioned. For example, an ion-exchange fiber can significantly increase the absorbent capacity of an absorbent fiber. The increased absorbent capacity may allow the amount of absorbent used in a dressing or container to be reduced, enabling a smaller dressing or container to be used, for example. In addition, using less absorbent material can provide a potential cost savings. For example, reducing use of SAP may decrease the cost to produce the absorbent and decrease the cost of other materials, such as drapes or wicking layers, for example. The gram-for-gram fluid management capacity of a dressing can be improved without relying on other factors such as evaporation.

[0060] Additionally, an ion-exchange fiber with a super-absorbent may be advantageous for producing a low profile dressing. For example, by combining a super-absorbent core and IEM together in the manner described above, the net efficiency of an

absorbent dressing may be significantly improved. In some instances, for example, the net efficiency can be increased by approximately 25%, whether or not the dressing is under compression. Furthermore, by disposing a water-permeable layer including IEM around a super-absorbent core, structural integrity can be added to the absorbent structure, which can prevent the structure from becoming dissociated when at full absorptive capacity or during dressing changes. Similarly, by binding an IEM to an absorbent fiber, the chances of the IEM being free or mobile are reduced.

[0061] While some exemplary embodiments are described in the context of reduced-pressure therapy applications, many of the features and advantages are readily applicable to other environments and industries.

[0062] Although certain illustrative, non-limiting exemplary embodiments have been presented, various changes, substitutions, permutations, and alterations can be made without departing from the scope of the appended claims. Any feature described in connection to any one exemplary embodiment may also be applicable to any other exemplary embodiment.

[0063] Further, the steps of the methods described herein may be carried out in any suitable order, or simultaneously where appropriate.

## CLAIMS

What is claimed is:

1. A fiber, comprising:
  - an absorbent core;
  - a filter layer disposed around the absorbent core; and
  - an ion-exchange media disposed in the filter layer and adapted to reduce an ionic concentration of a fluid.
2. The fiber of claim 1, wherein the filter layer is coated on the absorbent core.
3. The fiber of claim 1, wherein the filter layer encloses the absorbent core.
4. The fiber of any of claims 1-3, wherein the ion-exchange media comprises a cation-exchange media.
5. The fiber of any of claims 1-3, wherein the ion-exchange media comprises an anion-exchange media.
6. The fiber of any of claims 1-3, wherein the ion-exchange media comprises:
  - cation-exchange media;
  - anion-exchange media; and
  - the cation-exchange media and the anion-exchange media are dispersed throughout the filter layer.
7. The fiber of claim 1, wherein the ion-exchange media comprises porous beads formed from cross-linked polymers doped or grafted with acidic polymers.
8. The fiber of claim 7, wherein the cross-linked polymers comprise polystyrene and the acidic polymers comprise poly (2-acrylamido-2-methyl-1-propanesulfonic acid) and poly (acrylamido-*N*-propyltrimethylammonium chloride).
9. The fiber of claim 1, wherein the ion-exchange media comprises an alkaline polymer.
10. The fiber of claim 9, wherein the alkaline polymer is poly(acrylamido-*N*-propyltrimethylammonium chloride).

11. The fiber of claim 1, wherein the ion-exchange media comprises a zeolite.
12. The fiber of any of claims 1-11, wherein the filter layer is water-permeable.
13. The fiber of any of claims 1-11, wherein the filter layer comprises a polymer coating.
14. The fiber of claim 13, wherein the polymer coating comprises at least one of cross-linked polyvinyl alcohol, polyvinyl pyrrolidone, polyurethane, polyacrylamide, and polyethylene oxide.
15. The fiber of any of claims 1-14, wherein the absorbent core comprises a super-absorbent material.
16. The fiber of claim 15, wherein the super-absorbent material is a super-absorbent polymer.
17. The fiber of claim 16, wherein the super-absorbent polymer is a hydrogel.

18. An absorbent dressing for treating a tissue site, comprising:
  - an ion-exchange media adapted to reduce an ionic concentration of fluid from the tissue site; and
  - an absorbent adapted to absorb fluid with the reduced ionic concentration.
19. The absorbent dressing of claim 18, wherein the absorbent is formed into a plurality of absorbent fibers.
20. The absorbent dressing of any of claims 18-19, wherein the ion-exchange media comprises a cation-exchange media.
21. The absorbent dressing of any of claims 18-19, wherein the ion-exchange media comprises an anion-exchange media.
22. The absorbent dressing of any of claims 18-21, wherein the ion-exchange media is dispersed in a filter layer around the absorbent.
23. The absorbent dressing of claim 18, wherein:
  - the absorbent comprises an absorbent strand; and
  - the ion-exchange media is dispersed in strands twisted around the absorbent strand.
24. The absorbent dressing of any of claims 18-23, wherein the absorbent comprises a super-absorbent material.
25. The absorbent dressing of claim 24, wherein the super-absorbent material is a super-absorbent polymer.
26. The absorbent dressing of claim 18, wherein the absorbent is a fiber core and the ion-exchange media is dispersed in a layer around the fiber core.
27. The absorbent dressing of claim 26, wherein the ion-exchange media is dispersed in a polymer coating around the fiber core.

28. A system for treating a tissue site, comprising:
- a reduced-pressure source;
  - an absorbent layer adapted to be in fluid communication with the reduced-pressure source, the absorbent layer comprising:
    - an absorbent material adapted to absorb fluid from the tissue site, and
    - an ion-exchange media adapted to reduce an ionic concentration of the fluid; and
  - a drape adapted to cover the absorbent layer.
29. The system of claim 28, further comprising a container having an absorbent sheet disposed therein, and adapted to be in fluid communication with the tissue site and the reduced-pressure source.
30. The system of any of claims 28-29, further comprising a manifold adapted to be positioned between the absorbent layer and the tissue site.
31. The system of any of claims 28-30, wherein the ion-exchange media comprises porous beads formed from cross-linked polymers doped or grafted with acidic polymers.



32. A container for storing fluids from a tissue site, comprising:
- a body having an interior, a fluid inlet, and a fluid outlet; and
  - an absorbent layer disposed in the interior, the absorbent layer comprising:
    - an absorbent material, and
    - an ion-exchange media adapted to reduce an ionic concentration of fluid in the interior.
33. The container of claim 32, wherein the ion-exchange media is disposed around the absorbent material to form fibers.
34. The container of claim 32, wherein the ion-exchange media comprises porous beads formed from cross-linked polymers doped or grafted with acidic polymers.
35. The container of claim 34, wherein the cross-linked polymers comprise polystyrene and the acidic polymers comprise poly (2-acrylamido-2-methyl-1-propanesulfonic acid) and poly (acrylamido-*N*-propyltrimethylammonium chloride).
36. The container of claim 32, wherein the ion-exchange media comprises a zeolite.



37. A method for treating a tissue site, comprising:
- disposing an absorbent layer proximate to the tissue site; and
  - attaching the absorbent layer to the tissue site with a drape, wherein the absorbent layer comprises:
    - an absorbent material, and
    - an ion-exchange media adapted to reduce an ionic concentration of a fluid drawn into the absorbent layer.
38. The method of claim 37, further comprising:
- disposing a manifold between the tissue site and the absorbent layer;
  - fluidly coupling a reduced-pressure source to the manifold; and
  - supplying reduced pressure to the tissue site to draw fluid from the tissue site to the absorbent layer.
39. The method of claim 38, further comprising fluidly coupling a container between the manifold and the reduced-pressure source, wherein a second absorbent layer is positioned in the container.

40. A system for treating a tissue site, comprising:
- a reduced-pressure source for providing reduced pressure;
  - a fluid storage member adapted to be in fluid communication with the tissue site and the reduced-pressure source to collect fluid from the tissue site;
  - a manifold adapted to receive reduced pressure and distribute the reduced pressure across the tissue site;
  - a drape adapted to cover the manifold and provide a substantially fluid-tight seal at the tissue site; and
  - an absorbent layer adapted to be in fluid communication with the reduced-pressure source, comprising:
    - a carrier, and
    - a plurality of multi-layer fibers, wherein each multi-layer fiber comprises an ion-exchange media disposed around an absorbent core.
41. The systems, apparatuses, and methods substantially as described herein.

1/3



2/3




FIG. 3




FIG. 4

3/3




FIG. 5




FIG. 6

## INTERNATIONAL SEARCH REPORT

International application No

PCT/US2015/053018

#### A. CLASSIFICATION OF SUBJECT MATTER

INV.    A61F13/00                    A61F13/02

ADD.

**According to International Patent Classification (IPC) or to both national classification and IPC**

### B. FIELDS SEARCHED

**Minimum documentation searched (classification system followed by classification symbols)**

A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal , WPI Data

### C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y   A	<p>US 2007/044903 A1 (WISNESKI ANTHONY J [US] ET AL) 1 March 2007 (2007-03-01) paragraph [0051]</p> <p>-----</p> <p>- / - -</p>	<p>1,3,12, 15-17</p> <p>2,4-11, 13,14, 18-22, 24-32, 34-36</p> <p>23,33,40</p>

<input checked="checked" type="checkbox"/>	Further documents are listed in the continuation of Box C.
--	--

**X** See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

**"E" earlier application or patent but published on or after the international filing date**

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

**"P" document published prior to the international filing date but later than the priority date claimed**

**"T"** later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

6 November 2015

Date of mailing of the international search report

17/11/2015

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040,  
Fax: (+31-70) 340-3016

**Authorized officer**

Gennari , Silvia

# INTERNATIONAL SEARCH REPORT

International application No  
PCT/US2015/053018

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2005/051461 A1 (SMITH & NEPHEW [GB] ; BLOTT PATRICK LEWIS [GB] ; GREENER BRYAN [GB]; HAR) 9 June 2005 (2005-05-09)	18,20, 21,28-30
Y	claims 1-10; figures 1-15	2,4-12, 14,19, 22, 24-27, 31,32, 34-36
A		23,33,40
X	----- W0 2009/157877 A1 (TEMASEK POLYTECHNIC [SG]; TAN KIM CHENG [SG] ; BLUCHEL CHRISTIAN GERT ( ) 30 December 2009 (2009-12-30)	32,36
Y	page 3 - page 5	12,13, 18,20, 21, 28-31, 34,35
A		33
X	----- US 2014/200532 A1 (ROBINSON TIMOTHY MARK [GB] ET AL) 17 July 2014 (2014-07-17)	18-21, 24,25, 28-32, 34-36
Y	claims 1-44; figures 1-5	8,10,22, 26,27
A	-----	23,33,40

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US2015/053018

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 37-39  
because they relate to subject matter not required to be searched by this Authority, namely:  
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. ☒ Claims Nos.: 41  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/21Q
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☒ No protest accompanied the payment of additional search fees.



## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Claims Nos.: 37-39

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

-----

Continuation of Box II.2

Claims Nos.: 41

Subject matter of claim too vague and unclear, too many combinations of features possible

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guidelines C-IV, 7.2), should the problems which led to the Article 17(2) declaration be overcome.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2015/053018

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2007044903	AI	01-03-2007	AU 2006285363 AI 08-03-2007
			BR PIQ614615 A2 12-04-2011
			EP 1919413 AI 14-05-2008
			JP 2009505783 A 12-02-2009
			KR 20080039455 A 07-05-2008
			US 2007044903 AI 01-03-2007
			WO 2007027287 AI 08-03-2007
			ZA 200800845 A 26-08-2009
-----			
WO 2005051461	AI	09-06-2005	AU 2004292383 AI 09-06-2005
			CA 2540878 AI 09-06-2005
			CA 2739605 AI 09-06-2005
			CA 2821842 AI 09-06-2005
			CN 1874806 A 06-12-2006
			DK 1684826 T3 16-06-2014
			EP 1684826 AI 02-08-2006
			EP 2298381 AI 23-03-2011
			EP 2311509 AI 20-04-2011
			ES 2459340 T3 09-05-2014
			ES 2511965 T3 23-10-2014
			JP 4680921 B2 11-05-2011
			JP 5260588 B2 14-08-2013
			JP 5324686 B2 23-10-2013
			JP 2007509680 A 19-04-2007
			JP 2010137084 A 24-06-2010
			JP 2012196531 A 18-10-2012
			KR 20060096067 A 05-09-2006
			KR 20110058915 A 01-06-2011
			KR 20110120955 A 04-11-2011
			US 2007167926 AI 19-07-2007
			US 2010298793 AI 25-11-2010
			US 2011054423 AI 03-03-2011
			US 2012041399 AI 16-02-2012
			US 2012053538 AI 01-03-2012
			US 2012109084 AI 03-05-2012
			US 2015165101 AI 18-06-2015
			WO 2005051461 AI 09-06-2005
			ZA 200602867 A 29-08-2007
-----			
WO 2009157877	AI	30-12-2009	AU 2009263045 AI 30-12-2009
			AU 2009263046 AI 30-12-2009
			CN 102123749 A 13-07-2011
			CN 102176934 A 07-09-2011
			EP 2303354 AI 06-04-2011
			EP 2310069 AI 20-04-2011
			JP 5439482 B2 12-03-2014
			JP 2011525403 A 22-09-2011
			JP 2011525404 A 22-09-2011
			JP 2015013129 A 22-01-2015
			NZ 590467 A 28-03-2013
			NZ 590471 A 26-04-2013
			RU 2011102163 A 27-07-2012
			RU 2011102164 A 27-07-2012
			TW 201008637 A 01-03-2010
			TW 201014622 A 16-04-2010
			US 2011171713 AI 14-07-2011
			US 2011184340 AI 28-07-2011
			WO 2009157877 AI 30-12-2009

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2015/053018

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		WO 2009157878 AI	30-12-2009
-----			
US 2014200532 AI	17-07-2014	EP 2945659 A2	25-11-2015
		US 2014200532 AI	17-07-2014
		WO 2014113249 A2	24-07-2014
-----			